Women in Business: Marina Rajic, CEO BioViros
Tell readers what it is that you do? At BioViros, we make special tools called viral vectors to help fight cancer. Imagine these as tiny delivery vans. We take a harmless virus, remove its contents, and put in a special package instead. This package has instructions that can teach our own immune system to recognise and fight cancer. We produce these viral vectors in large quantities so they can be used in cancer treatments. It’s a bit like running a factory that makes special delivery vans, but these vans are 0.000000001 meters in size, and their cargo is to equip our white blood cells. So far, we have established a laboratory for production in Lower Hutt, and hired key people to do run the process in NZ. As we expand in 2023, we are prioritising communication with our investors, understanding that their partnership is crucial for the team growth and production scale up to enable production of viral vectors for clinical trials in NZ and beyond. Where are the opportunities in Bio Tech? In the last couple of years, we’ve seen a growth of FDA approved drugs for cell and gene therapy. We have decided to dive deeper into this and place our bets on viral vector manufacturing. I hope to see New Zealand attracting a lot of talent in the field of cell therapy in the very near future. Globally we will also probably see a shift towards personalised medicine, driven by genomics and bioinformatics where precise algorithms can tailor the treatments for individual patients. Does BioViros have overseas markets? A large portion of BioViros market will be overseas. We’ve talked to people from Australia, US and will look into Asia as well. Customers are mainly interested in sourcing a high-quality product without the fear of delays, because that […]